# Letermovir for CMV Prevention After Lung Transplantation

> **NCT05041426** · PHASE2 · COMPLETED · sponsor: **Fernanda P Silveira, MD, MS** · enrollment: 15 (actual)

## Conditions studied

- Lung Transplant
- CMV

## Interventions

- **DRUG:** Letermovir
- **DRUG:** Valganciclovir

## Key facts

- **NCT ID:** NCT05041426
- **Lead sponsor:** Fernanda P Silveira, MD, MS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-06
- **Primary completion:** 2025-03-03
- **Final completion:** 2025-03-03
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05041426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05041426, "Letermovir for CMV Prevention After Lung Transplantation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05041426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*